Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, Phase 1b study of pembrolizumab for patients with
myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic
leukemia (ALL) whose disease has relapsed after receiving allogeneic hematopoetic stem cell
transplant.
Phase:
Phase 1
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center